PRECIGEN, INC. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
PRECIGEN, INC. (PGEN) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $2.95 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2019-03-01
- PRECIGEN, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2018 was $2.95M, a 0.00% change from fiscal 2017.
- PRECIGEN, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2017 was $2.95M.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|
| 2018-12-31 | $2.95M 10-K · filed 2019-03-01 |
| 2017-12-31 | $2.95M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |